These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 14593726)

  • 1. Tubulin and microtubules as targets for anticancer drugs.
    Hadfield JA; Ducki S; Hirst N; McGown AT
    Prog Cell Cycle Res; 2003; 5():309-25. PubMed ID: 14593726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microtubule active agents: beyond the taxane frontier.
    Morris PG; Fornier MN
    Clin Cancer Res; 2008 Nov; 14(22):7167-72. PubMed ID: 19010832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on tubulin-binding agents.
    Attard G; Greystoke A; Kaye S; De Bono J
    Pathol Biol (Paris); 2006 Mar; 54(2):72-84. PubMed ID: 16545633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microtubules: a dynamic target in cancer therapy.
    Pasquier E; Kavallaris M
    IUBMB Life; 2008 Mar; 60(3):165-70. PubMed ID: 18380008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer therapy with novel tubulin-interacting drugs.
    Kavallaris M; Verrills NM; Hill BT
    Drug Resist Updat; 2001 Dec; 4(6):392-401. PubMed ID: 12030786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Progress in the study of tubulin inhibitors].
    Shang H; Pan L; Yang S; Chen H; Cheng MS
    Yao Xue Xue Bao; 2010 Sep; 45(9):1078-88. PubMed ID: 21351562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microtubule alterations and resistance to tubulin-binding agents (review).
    Drukman S; Kavallaris M
    Int J Oncol; 2002 Sep; 21(3):621-8. PubMed ID: 12168109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity.
    Aparicio LM; Pulido EG; Gallego GA
    Anticancer Drugs; 2012 Jan; 23(1):1-11. PubMed ID: 22027536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrotubular drugs binding to vinca domain of tubulin.
    Gupta S; Bhattacharyya B
    Mol Cell Biochem; 2003 Nov; 253(1-2):41-7. PubMed ID: 14619954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.
    Perez EA
    Mol Cancer Ther; 2009 Aug; 8(8):2086-95. PubMed ID: 19671735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microtubule assembly dynamics: an attractive target for anticancer drugs.
    Singh P; Rathinasamy K; Mohan R; Panda D
    IUBMB Life; 2008 Jun; 60(6):368-75. PubMed ID: 18384115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
    Kuo CC; Hsieh HP; Pan WY; Chen CP; Liou JP; Lee SJ; Chang YL; Chen LT; Chen CT; Chang JY
    Cancer Res; 2004 Jul; 64(13):4621-8. PubMed ID: 15231674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
    Tangutur AD; Kumar D; Krishna KV; Kantevari S
    Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laulimalide and paclitaxel: a comparison of their effects on tubulin assembly and their synergistic action when present simultaneously.
    Gapud EJ; Bai R; Ghosh AK; Hamel E
    Mol Pharmacol; 2004 Jul; 66(1):113-21. PubMed ID: 15213302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tubulin inhibitors: a patent review.
    Liu YM; Chen HL; Lee HY; Liou JP
    Expert Opin Ther Pat; 2014 Jan; 24(1):69-88. PubMed ID: 24313741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorescence spectroscopic methods to analyze drug-tubulin interactions.
    Bhattacharyya B; Kapoor S; Panda D
    Methods Cell Biol; 2010; 95():301-29. PubMed ID: 20466142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can mutations in gamma-actin modulate the toxicity of microtubule targeting agents?
    Fojo T
    J Natl Cancer Inst; 2006 Oct; 98(19):1345-7. PubMed ID: 17018774
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular modelling studies on Arylthioindoles as potent inhibitors of tubulin polymerization.
    Coluccia A; Sabbadin D; Brancale A
    Eur J Med Chem; 2011 Aug; 46(8):3519-25. PubMed ID: 21621885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Application of NGF/PC12 cell system for screening tubulin inhibitors].
    Kohno M; Hattori A; Yamaguchi H
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):164-77. PubMed ID: 9030227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-(2,6-dimethoxypyridine-3-yl)-9-methylcarbazole-3-sulfonamide as a novel tubulin ligand against human cancer.
    Wang YM; Hu LX; Liu ZM; You XF; Zhang SH; Qu JR; Li ZR; Li Y; Kong WJ; He HW; Shao RG; Zhang LR; Peng ZG; Boykin DW; Jiang JD
    Clin Cancer Res; 2008 Oct; 14(19):6218-27. PubMed ID: 18829501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.